Genmab AS (GMAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $31.80B
Last updated: Nov 17, 2026 at 4:33 PM ET
Genmab AS (GMAB) Statistics
Genmab AS (GMAB) has a market cap of $31.80B. Its trailing P/E is 36.1x.
Total Valuation
| Market Cap | $31.80B |
|---|---|
| Latest price (Nov 17, 2026) | $51.96 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 19.3x and 5.1x.
| P/E Ratio | 36.1x |
|---|---|
| P/S Ratio | 19.3x |
| P/B Ratio | 5.1x |
| P/FCF Ratio | 57.5x |
| PEG Ratio | 5.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 58.8x EBITDA and 63.0x free cash flow.
| EV / EBITDA | 58.8x |
|---|---|
| EV / FCF | 63.0x |
Price Statistics
The stock is up 71.71% over 52 weeks and trades 24.07% above its 50-day average.
| Beta (1Y) | 0.89 |
|---|---|
| 52-Week Change | +71.71% |
| 1-Month Change | +34.96% |
| 3-Month Change | +52.33% |
| 6-Month Change | +102.34% |
| 5-Year Change | +27.82% |
| 10-Year Change | +242.21% |
| Total Return (1Y) | +71.71% |
| Total Return (3Y CAGR) | +16.57% |
| Total Return (5Y CAGR) | +4.17% |
| Return vs SPY (1Y) | +59.81% |
| Max Drawdown (1Y) | -32.51% |
| Max Drawdown (3Y) | -45.13% |
| Sharpe Ratio (1Y) | 1.24 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $41.88 |
| 200-Day Average | $31.73 |
| 52-Week Range | $23.62 to $59.97 |
| RSI (14 Days) | 60.4 |
| Average Volume (20 Days) | 6.43M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.45x current liabilities, and total debt is 0.79x shareholder equity.
| Current Ratio | 2.45x |
|---|---|
| Quick Ratio | 2.43x |
| Debt / Equity | 0.79x |
| Debt / EBITDA | 8.29x |
| Interest Coverage | 3.76x |
Returns and Efficiency
Return on invested capital is 4.83% over the last 12 months, against a 5-year average of 15.55%.
| Return on Assets (ROA) | 3.10% |
|---|---|
| Return on Invested Capital (ROIC) | 4.83% |
| ROIC (5Y Average) | 15.55% |
| Inventory Turnover | 7.55x |
| Receivables Turnover | 2.23x |
Scores
GMAB has an Altman Z-Score of 3.90, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.90 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Dividends and Yields
GMAB does not pay a dividend. Its free cash flow yield is 1.74%.
| Earnings Yield | 2.77% |
|---|---|
| FCF Yield | 1.74% |
Stock Splits
The last split was a 5-for-1 forward split on May 1, 2018.
| Last Split Date | May 1, 2018 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 5:1 |
Peer Position
Against 5 similar companies, GMAB has the 2nd highest P/E.
P/E RatioPeer median 19.7x
P/S RatioPeer median 16.7x
ROICPeer median -12.70%
| P/E Ratio | 36.1x vs 19.7x median |
|---|---|
| P/S Ratio | 19.3x vs 16.7x median |
| ROIC | 4.83% vs -12.70% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GMAB
What is GMAB's market cap?
Genmab AS has a market cap of $31.80B.
What is GMAB's P/E ratio?
Genmab AS has a trailing P/E ratio of 36.1x.
How many shares of GMAB are outstanding?
Genmab AS has 620.69M shares outstanding. The count is down 0.01% from a year earlier.
Does GMAB pay a dividend?
No. Genmab AS does not pay a dividend.
GMAB pages: Overview, Charting, Statistics, Valuation, Competitors